HemaCell Therapeutics closes Series B1 first tranche and secures credit lines, raising ¥200M+ for platelet regeneration

Recently, HemaCell Therapeutics announced the completion of its Series B1 equity financing round, raising over 100 million RMB. The company also secured over 100 million RMB in credit-based debt financing from multiple banks. These funds will be dedicated to advancing HemaCell's core business: the ex vivo regeneration of platelet lineages. This technology aims to address critical issues such as blood supply shortages and blood-borne diseases, significantly reduce adverse outcomes associated with blood transfusions, and facilitate the development of novel therapeutics derived from these regenerated platelets.

This initial closing of the Series B1 round was led by Hainan Health Medical Group, with participation from investors including Varangian Venture, and the total equity financing exceeded 100 million RMB. The proceeds will be primarily allocated to advance clinical trials for the company's first two pipelines and to support preclinical work for other key pipelines, fueling HemaCell's rapid growth. Concurrently, the second closing of the Series B1 round is underway and is expected to be finalized within the coming months.

HemaCell Therapeutics has achieved significant milestones with its two internally developed, "first-in-class" megakaryocyte products, which have received Investigational New Drug (IND) application approvals from the U.S. Food and Drug Administration (FDA) and China's National Medical Products Administration (NMPA), respectively.

These products utilize hematopoietic stem cells as the source material, without any genetic editing. Through a serum-free, feeder-free, non-immortalization, and contaminant-free directed induction and differentiation system, they generate high-quality, large-scale, stable, and controllable megakaryocytes, targeting the vast global platelet-boosting drug market.

Furthermore, based on HemaCell's pipeline development progress, approximately four to five new drug IND applications are expected to enter the approval process around 2026.

HemaCell has also demonstrated exceptional performance in developing a "first-in-class" platelet infusion product derived from ex vivo induction and differentiation, securing multiple pioneering Orphan Drug Designations (ODD) from the FDA. These include ODDs for platelet infusions derived from both hematopoietic stem cells and induced pluripotent stem cells (iPSCs). According to statistics, HemaCell has been granted a total of five ODDs and two Rare Pediatric Disease Designations (RPDD) by the FDA, offering new therapeutic avenues for rare blood disorders.

Following this funding round, HemaCell will also initiate the development of its global operations.